HeadInvest LLC’s Bristol-Myers Squibb BMY Stock Holding History

HeadInvest LLC’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$442K	Sell	7,286 -1,862	-20%	-$109K	0.09%	158
2025 Q4	$491K	Sell	9,148 -2,306	-20%	-$111K	0.1%	151
2025 Q3	$517K	Sell	11,454 -875	-7%	-$40.9K	0.11%	141
2025 Q2	$571K	Sell	12,329 -690	-5%	-$33.9K	0.12%	133
2025 Q1	$794K	Sell	13,019 -3,027	-19%	-$176K	0.15%	119
2024 Q4	$908K	Sell	16,046 -2,301	-13%	-$129K	0.17%	102
2024 Q3	$949K	Sell	18,347 -1,096	-6%	-$51.4K	0.18%	99
2024 Q2	$807K	Buy	19,443 +1,072	+6%	+$48K	0.16%	107
2024 Q1	$996K	Buy	18,371 +2,019	+12%	+$103K	0.19%	89
2023 Q4	$839K	Sell	16,352 -1,711	-9%	-$89.8K	0.17%	95
2023 Q3	$1.04M	Sell	18,063 -1,080	-6%	-$66.2K	0.23%	81
2023 Q2	$1.17M	Sell	19,143 -9,787	-34%	-$656K	0.25%	78
2023 Q1	$2.01M	Sell	28,930 -1,725	-6%	-$122K	0.44%	52
2022 Q4	$2.21M	Buy	30,655 +2,654	+9%	+$200K	0.49%	51
2022 Q3	$1.99M	Sell	28,001 -50	-0.2%	-$3.63K	0.48%	52
2022 Q2	$2.16M	Buy	28,051 +355	+1%	+$27K	0.48%	54
2022 Q1	$2.02M	Buy	27,696 +893	+3%	+$60K	0.39%	58
2021 Q4	$1.67M	Sell	26,803 -240	-0.9%	-$14.1K	0.3%	68
2021 Q3	$1.6M	Buy	27,043 +920	+4%	+$60.6K	0.3%	65
2021 Q2	$1.75M	Buy	26,123 +1,667	+7%	+$109K	0.33%	59
2021 Q1	$1.54M	Buy	24,456 +110	+0.5%	+$6.84K	0.31%	62
2020 Q4	$1.51M	Buy	24,346 +2,670	+12%	+$164K	0.32%	61
2020 Q3	$1.31M	Buy	21,676 +1,812	+9%	+$109K	0.38%	56
2020 Q2	$1.17M	Buy	19,864 +2,317	+13%	+$139K	0.37%	59
2020 Q1	$978K	Buy	17,547 +5,582	+47%	+$341K	0.37%	58
2019 Q4	$768K	Buy	11,965 +7,715	+182%	+$442K	0.22%	77
2019 Q3	$216K	Sell	4,250 -8,000	-65%	-$376K	0.07%	177
2019 Q2	$556K	Hold	12,250	–	–	0.16%	94
2019 Q1	$584K	Sell	12,250 -12,250	-50%	-$610K	0.16%	90
2018 Q4	$1.27M	Buy	24,500 +11,850	+94%	+$637K	0.2%	81
2018 Q3	$785K	Sell	12,650 -77	-0.6%	-$4.57K	0.23%	76
2018 Q2	$704K	Sell	12,727 -48	-0.4%	-$2.59K	0.21%	80
2018 Q1	$808K	Hold	12,775	–	–	0.26%	70
2017 Q4	$783K	Hold	12,775	–	–	0.24%	74
2017 Q3	$788K	Buy	12,775 +100	+0.8%	+$5.84K	0.25%	74
2017 Q2	$706K	Hold	12,675	–	–	0.23%	76
2017 Q1	$689K	Buy	12,675 +2,375	+23%	+$130K	0.23%	76
2016 Q4	$602K	Buy	10,300 +700	+7%	+$38.3K	0.22%	77
2016 Q3	$478K	Sell	9,600 -2,600	-21%	-$167K	0.17%	85
2016 Q2	$897K	Sell	12,200 -200	-2%	-$14.1K	0.34%	61
2016 Q1	$792K	Sell	12,400 -267	-2%	-$16.8K	0.31%	61
2015 Q4	$871K	Hold	12,667	–	–	0.35%	57
2015 Q3	$750K	Sell	12,667 -855	-6%	-$54.2K	0.3%	59
2015 Q2	$900K	Hold	13,522	–	–	0.33%	60
2015 Q1	$872K	Buy	13,522 +200	+2%	+$12.5K	0.31%	61
2014 Q4	$786K	Hold	13,322	–	–	0.31%	60
2014 Q3	$775K	Hold	13,322	–	–	0.31%	61
2014 Q2	$646K	Hold	13,322	–	–	0.26%	61
2014 Q1	$692K	Sell	13,322 -100	-0.7%	-$5.32K	0.3%	58
2013 Q4	$713K	Hold	13,422	–	–	0.3%	59
2013 Q3	$621K	Sell	13,422 -132	-1%	-$5.79K	0.27%	63
2013 Q2	$606K	Buy	+13,554	New	+$588K	0.27%	61

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HeadInvest LLC's BMY Position: Q1 2026 in Review

HeadInvest LLC reduced its Bristol-Myers Squibb (BMY) stake by 20% in Q1 2026, selling an estimated $109K and leaving 7,286 shares worth $442K. The position accounts for 0.09% of the portfolio, ranked #158.

HeadInvest LLC first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.21M in Q4 2022. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

HeadInvest LLC held 7,286 shares of Bristol-Myers Squibb worth $442K as of Q1 2026.
HeadInvest LLC sold 1,862 Bristol-Myers Squibb shares in Q1 2026, an estimated $109K.
Bristol-Myers Squibb made up 0.09% of HeadInvest LLC's portfolio in Q1 2026, its #158 holding.
HeadInvest LLC first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
HeadInvest LLC's Bristol-Myers Squibb position peaked at $2.21M in Q4 2022.
2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on HeadInvest LLC's 13F filing for Q1 2026, filed 15 May 2026.